Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
156.27
Oct 22 • 3:59 PM ET Dollar change+2.34 Percentage change(1.52%)
Aftermarket Close
156.22
Aftermarket • 7:48 PM ET Dollar change-0.05 Percentage change(-0.03%)
Index
-
Market Cap
286.06B
Enterprise Value
327.79B
Income
12.76B
Sales
54.79B
Book/sh
22.69
Cash/sh
4.20
Employees
75267
IPO
Nov 07, 1996
P/E
23.57
Forward P/E
15.95
PEG
2.55
P/S
5.22
P/B
6.89
P/C
37.20
P/FCF
17.05
EV/EBITDA
15.31
EV/Sales
5.98
Quick Ratio
0.67
Current Ratio
0.86
Debt/Eq
1.18
LT Debt/Eq
0.94
Option/Short
Yes / Yes
EPS (ttm)
6.63
EPS next Y
9.80
EPS next Q
2.27
EPS this Y
-1.96%
EPS next Y
11.28%
EPS next 5Y
6.25%
EPS past 3/5Y
31.40% 15.24%
Sales past 3/5Y
9.03% 2.29%
EPS Y/Y TTM
-4.08%
Sales Y/Y TTM
2.33%
EPS Q/Q
-18.54%
Sales Q/Q
0.97%
Insider Own
0.01%
Insider Trans
0.00%
Inst Own
7.45%
Inst Trans
-0.25%
ROA
11.27%
ROE
30.56%
ROIC
15.82%
Gross Margin
74.08%
Oper. Margin
29.58%
Profit Margin
23.29%
SMA20
6.94%
SMA50
5.50%
SMA200
3.23%
Trades
Shs Outstand
1.83B
Shs Float
1.83B
52W High
170.46 -8.32%
52W Low
121.57 28.54%
Volatility
1.11% 1.28%
ATR (14)
2.65
RSI (14)
70.65
Beta
0.43
Rel Volume
1.08
Avg Volume
1.92M
Volume
2,081,381
Perf Week
3.92%
Perf Month
9.50%
Perf Quarter
0.81%
Perf Half Y
5.96%
Perf YTD
13.35%
Perf Year
18.90%
Perf 3Y
65.05%
Perf 5Y
94.47%
Perf 10Y
144.07%
Prev Close
153.93
Price
156.27
Change %
1.52%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bulto Carulla VictorOfficerApr 30 '26Proposed Sale148.106,8001,007,093Apr 30 12:05 PM
Marshall FionaOfficerFeb 12 '26Proposed Sale161.3530,7434,960,277Feb 12 02:43 PM
Bulto Carulla VictorOfficerFeb 09 '26Proposed Sale156.217,5001,171,576Feb 09 11:49 AM
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Chief Executive OfficerDr. Vasant Narasimhan M.D.
President of USMr. Victor Bulto
President of InternationalDr. Patrick Horber M.D.
Chief Financial OfficerMr. Mukul Mehta
President of OperationsDr. Steffen Lang Ph.D.